In light of the findings of an October 19 Journal of the American Medical Association (JAMA) study that found that fish oil docosahexaenoic acid (DHA) does not aid against postpartum depression, the Council for Responsible Nutrition (CRN) says that a strong body of scientific evidence does support DHA’s use throughout pregnancy.
In light of the findings of an October 19 Journal of the American Medical Association (JAMA) study that found that fish oil docosahexaenoic acid (DHA) does not aid against postpartum depression, the Council for Responsible Nutrition (CRN) says that a strong body of scientific evidence does support DHA’s use throughout pregnancy.
CRN says that more research should be done to determine the effects of DHA on postpartum depression and fetal brain development.
“A large body of scientific evidence has established a strong relationship between the DHA status of mothers and infants and a variety of important pregnancy-related outcomes, including infant development,” says Duffy MacKay, CRN’s vice president of scientific and regulatory affairs.
MacKay pointed out some study flaws, saying that the subjects’ DHA levels were not measured pre-pregnancy or when they were evaluated for depression. DHA levels were also not measured in infants at 18 months, when they were studied for neurological outcomes.
“Without measurements of DHA status, it is difficult to draw conclusions from the study and certainly should not provide definitive advice to consumers,” he says.
Read the association’s full response here.
Nutritional Outlook's Women in Nutraceuticals Roundtable: The Future of Women's Health Research
July 19th 2024Watch "The Future of Women's Health Research," a roundtable discussion presented by Nutritional Outlook in partnership with Women in Nutraceuticals. This roundtable is supplement to a recent article commissioned by WIN and published by Nutritional Outlook, titled “Taking Initiative: Can the WHI’s model help the nutraceutical industry answer questions the study didn’t even ask?”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.